ABBV-319
- Generic Name
- ABBV-319
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)
Phase 1
Not yet recruiting
- Conditions
- Dry Eye SyndromeSystemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT06977724
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
Phase 1
Recruiting
- Conditions
- Diffuse Large B-Cell LymphomaChronic Lymphocytic LeukemiaFollicular Lymphoma
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 154
- Registration Number
- NCT05512390
- Locations
- 🇺🇸
University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona, United States
🇺🇸Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232, Miami, Florida, United States
🇺🇸Allina Health System /ID# 251782, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath